Top 2026 Long Idea Competition: The Winners [Seeking Alpha]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Seeking Alpha
Stay tuned for details about upcoming competitions. In January, Seeking Alpha invited analysts to participate in a Top 2026 Long Idea competition . We received 50 submissions . Here's a look at all the winners as determined by the judging editors: The Value Puzzle – Global Payments: A Promising Setup For 2026 - GPN trades at a depressed valuation due to uncertainties surrounding its upcoming merger with Worldpay. With the deal likely closing Q1-2026, uncertainty should recede over the course of 2026 as investors get more comfortable with the newly created entity leading to a revaluation of GPN. Brendan O'Boyle – Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology - Jazz Pharmaceuticals is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts with 2026 a transitional year supporting long-term asymmetric upside. Wall Street Titan – Avita Medical: Set Up For A Turnaround - Avita Medical's innovative automate
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals (JAZZ) had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an "overweight" rating on the stock.MarketBeat
- Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026PR Newswire
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 3/9/26 - Form 4
- 3/9/26 - Form 4
- 3/9/26 - Form 4
- JAZZ's page on the SEC website